Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDResearch in context

Autor: Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Yu Gao, Gunnar Söderdahl, Anders Österborg, C.I.Edvard Smith, Jan Vesterbacka, David Wullimann, Angelica Cuapio, Mira Akber, Gordana Bogdanovic, Sandra Muschiol, Mikael Åberg, Karin Loré, Margaret Sällberg Chen, Per Ljungman, Marcus Buggert, Soo Aleman, Hans-Gustaf Ljunggren

Publikováno v: EBioMedicine, Vol 109, Iss , Pp 105385- (2024)

Summary: Background: Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating recommendations for additional booster doses. However, longitudinal data reflecting

Externí odkaz: https://doaj.org/article/e065b36ec6674ac794485395f839553b

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDResearch in context

Autor: Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Gunnar Söderdahl, Anders Österborg, C.I. Edvard Smith, Jan Vesterbacka, David Wullimann, Angelica Cuapio, Mira Akber, Gordana Bogdanovic, Sandra Muschiol, Mikael Åberg, Karin Loré, Margaret Sällberg Chen, Marcus Buggert, Per Ljungman, Soo Aleman, Hans-Gustaf Ljunggren

Publikováno v: EBioMedicine, Vol 94, Iss , Pp 104700- (2023)

Summary: Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses

Externí odkaz: https://doaj.org/article/2329229490de4fbd80902984341b218f

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals

Autor: Angelica Cuapio, Caroline Boulouis, Iva Filipovic, David Wullimann, Tobias Kammann, Tiphaine Parrot, Puran Chen, Mira Akber, Yu Gao, Quirin Hammer, Benedikt Strunz, André Pérez Potti, Olga Rivera Ballesteros, Joshua Lange, Jagadeeswara Rao Muvva, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Gunnar Söderdahl, Anders Österborg, C. I. Edvard Smith, Gordana Bogdanovic, Sandra Muschiol, Fredrika Hellgren, Karin Loré, Michal J. Sobkowiak, Giorgio Gabarrini, Katie Healy, Margaret Sällberg Chen, Evren Alici, Niklas K. Björkström, Marcus Buggert, Per Ljungman, Johan K. Sandberg, Soo Aleman, Hans-Gustaf Ljunggren

Publikováno v: Molecular Medicine, Vol 28, Iss 1, Pp 1-12 (2022)

Abstract Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK cells in healthy individuals a

Externí odkaz: https://doaj.org/article/385ad681ef5c4016a17b2e4b36257493

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Autor: Peter Bergman, MD, Ola Blennow, MD, Lotta Hansson, MD, Stephan Mielke, MD, Piotr Nowak, MD, Puran Chen, MD, Gunnar Söderdahl, MD, Anders Österborg, MD, C. I. Edvard Smith, MD, David Wullimann, MSc, Jan Vesterbacka, MD, Gustaf Lindgren, MD, Lisa Blixt, MD, Gustav Friman, MD, Emilie Wahren-Borgström, MD, Anna Nordlander, MD, Angelica Cuapio Gomez, MD, Mira Akber, MSc, Davide Valentini, MD, Anna-Carin Norlin, MD, Anders Thalme, MD, Gordana Bogdanovic, MD, Sandra Muschiol, PhD, Peter Nilsson, PhD, Sophia Hober, PhD, Karin Loré, PhD, Margaret Sällberg Chen, PhD, Marcus Buggert, PhD, Hans-Gustaf Ljunggren, MD, Per Ljungman, MD, Soo Aleman, MD

Publikováno v: EBioMedicine, Vol 74, Iss , Pp 103705- (2021)

Background: Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate safety and efficacy of BNT162b2 mRNA vaccination

Externí odkaz: https://doaj.org/article/4718ffd4f65749848e9d9b7f48c73d1b

Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age

Autor: Marion Humbert, Anna Olofsson, David Wullimann, Julia Niessl, Emma B. Hodcroft, Curtis Cai, Yu Gao, Ebba Sohlberg, Robert Dyrdak, Flora Mikaeloff, Ujjwal Neogi, Jan Albert, Karl-Johan Malmberg, Fridtjof Lund-Johansen, Soo Aleman, Linda Björkhem-Bergman, Maria C. Jenmalm, Hans-Gustaf Ljunggren, Marcus Buggert, Annika C. Karlsson

Publikováno v: Humbert, Marion; Olofsson, Anna; Wullimann, David; Niessl, Julia; Hodcroft, Emma B; Cai, Curtis; Gao, Yu; Sohlberg, Ebba; Dyrdak, Robert; Mikaeloff, Flora; Neogi, Ujjwal; Albert, Jan; Malmberg, Karl-Johan; Lund-Johansen, Fridtjof; Aleman, Soo; Björkhem-Bergman, Linda; Jenmalm, Maria C; Ljunggren, Hans-Gustaf; Buggert, Marcus and Karlsson, Annika C (2023). Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age. Proceedings of the National Academy of Sciences of the United States of America-PNAS, 120(12), e2220320120. National Academy of Sciences NAS 10.1073/pnas.2220320120

Pre-existing SARS-CoV-2-reactive T cells have been identified in SARS-CoV-2-unexposed individuals, potentially modulating COVID-19 and vaccination outcomes. Here, we provide evidence that functional cross-reactive memory CD4 + T cell immunity against

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c09127d67724e3c693030b5303811a